Literature DB >> 3288531

In vitro studies of insulin resistance in patients with lipoatrophic diabetes. Evidence for heterogeneous postbinding defects.

J Magré1, C Reynet, J Capeau, M J Blivet, J Picard.   

Abstract

We studied the binding and action of insulin in cultured fibroblasts from six patients with lipoatrophic diabetes and marked in vivo insulin resistance and from seven control subjects. The binding of insulin was not altered, which corresponds well with studies with circulating erythrocytes. Similarly, the action of the hormone on amino acid uptake (estimated by active transport of aminoisobutyric acid) was comparable in patient and control cells. Conversely, studies concerning the effect of insulin on glucose transport (estimated by facilitated diffusion of 2-deoxyglucose) or glycogen synthesis (estimated by incorporation of glucose into cellular glycogen) revealed the presence of heterogeneous alterations among the different patient cell lines. However, although the nature of the defect(s) varied among the patients, alterations in glucose metabolism were present in all cases. These data suggest the presence of primary postbinding defects in glucose cellular pathways that give rise to insulin resistance in cells from lipoatrophic diabetic patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3288531     DOI: 10.2337/diab.37.4.421

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  2 in total

1.  Patients with lipodystrophic diabetes mellitus of the Seip-Berardinelli type, express normal insulin receptors.

Authors:  E R van der Vorm; A Kuipers; J W Bonenkamp; W J Kleijer; L Van Maldergem; J Herwig; J A Maassen
Journal:  Diabetologia       Date:  1993-02       Impact factor: 10.122

2.  The development of hyperglycaemia in patients with insulin-resistant generalized lipoatrophic syndromes.

Authors:  J J Robert; B Rakotoambinina; I Cochet; V Foussier; J Magre; D Darmaun; D Chevenne; J Capeau
Journal:  Diabetologia       Date:  1993-12       Impact factor: 10.122

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.